Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADP101 OIT Extension Study
NCT05243719Phase 2Terminated
- Sponsor
- Alladapt Immunotherapeutics
- Start
- Mar 2022
- Primary completion
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes, Allergy Immunotherapy
- Countries
- 1
01
Overview
A Phase 2 trial of ADP101 in food allergy, sponsored by Alladapt Immunotherapeutics. Started Mar 2022; status: terminated.
02
Drugs
ADP101
03
Conditions
food allergy
Beyond the preview
Go deeper on NCT05243719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05243719.